AMLX - NASDAQ

Amylyx Pharmaceuticals, Inc.

AMLX·NASDAQ

$14.31

+7.7%

HealthcareBiotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.19B

EPS-1.5300

P/E Ratio-9.35

Earnings Date08/06/2026

amlx

Cost of Revenue

Last Annual Value

525.00K

3-Year CAGR

-44%

5-Year CAGR

-54%

10-Year CAGR

-27%

Adjust for Inflation

Amylyx Pharmaceuticals, Inc. Competitors Analysis of Cost of Revenue

AMLX · NASDAQ

Company	Cost of Revenue	CAGR 3Y	CAGR 5Y	CAGR 10Y
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX	525.00K	-72.6%	N/A	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	3.56M	N/A	N/A	N/A
Nektar Therapeutics NASDAQ:NKTR	0.00	N/A	N/A	N/A
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX	6.97M	N/A	N/A	N/A
Precigen, Inc. NASDAQ:PGEN	6.10M	-0.1%	-35.3%	-20.7%
Atai Beckley Inc. NASDAQ:ATAI	1.01M	46.9%	84.8%	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	2.48M	27.7%	-1.6%	-17.5%
Sana Biotechnology, Inc. NASDAQ:SANA	12.75M	N/A	N/A	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	1.22M	5.7%	N/A	N/A

Amylyx Pharmaceuticals, Inc. Fair Value Envelope

AMLX · NASDAQ

Our analysis suggests that AMLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.31, this represents a potential HIDDEN relative to our calculated worth for Amylyx Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $14.31

Related Guides

Blog Categories

Continue your AMLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.